Radiobiology and Imaging Program

放射生物学和成像项目

• 批准号: 10330969
• 负责人: Amit Maity
• 金额: $ 8.49万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-15 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10330969
• 关键词: Address; Basic Science; Biological; Cancer Burden; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Clinical; Clinical Research; Clinical Trials; Collaborations; Community Outreach; Consultations; Department chair; Development; Direct Costs; Discipline of Nuclear Medicine; Disease; Doctor of Philosophy; Ensure; Environment; Funding; Goals; Hypoxia; Image; Imaging Device; Immune; Immune checkpoint inhibitor; Immune response; Immune system; Immunobiology; Immunotherapy; Intervention; Intervention Trial; Ions; Lead; Leadership; Malignant Neoplasms; Metabolic stress; Modality; Nonionizing Radiation; Normal tissue morphology; Patient-Focused Outcomes; Patients; Pediatric Oncology; Peer Review; Play; Protons; Publications; Radiation; Radiation Oncology; Radiation Tolerance; Radiation therapy; Radiobiology; Radiology Specialty; Radiopharmaceuticals; Research; Research Personnel; Research Project Grants; Resolution; Resource Sharing; Resources; Role; Schools; Senior Scientist; Testing; Therapeutic; Time; Translational Research; Tumor Biology; Tumor Tissue; Vision; Work; anti-cancer; cancer care; cancer therapy; checkpoint therapy; chimeric antigen receptor T cells; community engagement; design-build-test; environmental carcinogenesis; epidemiology study; imaging agent; imaging biomarker; imaging modality; imaging program; improved; innovation; investigator-initiated trial; malignant breast neoplasm; member; mid-career faculty; novel; nuclear division; optimal treatments; outreach; professor; programs; proton beam; proton therapy; recruit; research and development; response; theranostics; tobacco carcinogenesis; translational pipeline; translational study; treatment response; tumor metabolism; tumor microenvironment

PROJECT SUMMARY – Radiobiology and Imaging Program (RBI) The Radiobiology and Imaging Program (RBI) seeks to advance the understanding of the interaction of ionizing and non-ionizing radiation with cancer and normal tissues. RBI addresses the cancer burden within our catchment area through collaboration with our Community Outreach and Engagement (COE). Scientific Aims are to: 1) Develop and characterize agents to improve cancer therapy with radiation; 2) Investigate radiobiological or imaging methods of altering or interrogating the immune environment to improve therapeutic response; 3) Gain a deeper understanding of the tumor microenvironment (TME) and metabolism with the aim to leverage this understanding to improve therapeutic response; 4) Develop novel imaging to optimally guide cancer care; and 5) Understand the biological effects of protons to optimize their clinical use and determine which patients will benefit most from proton beam therapy. The Program is led by Amit Maity, MD, PhD, Professor and Executive Vice-Chair of the Department of Radiation Oncology, and Daniel Pryma, MD, Associate Professor of Radiology and Chief of the Division of Nuclear Medicine. Drs. Maity and Pryma are NCI-funded researchers who bring their scientific vision to this Program, which is focused on basic and translational research and the development of investigator-initiated trials. Since the last renewal, the Program Leaders recruited new junior and senior scientists, enhanced collaborative peer-reviewed funding, and more than doubled accruals to interventional clinical trials, especially investigator-initiated trials (which constitute 91.6% of interventional accruals). Drs. Maity and Pryma expanded the Program's focus on imaging modalities and theranostics and further enhanced the integration and interplay between radiobiology and imaging in RBI. A major development has been the substantial expansion of both translational and clinical studies of proton therapy. RBI has critical interactions with other ACC Programs including Tumor Biology, Immunobiology, Cancer Therapeutics, Breast Cancer, Cancer Control, Tobacco and Environmental Carcinogenesis, and Pediatric Oncology. The 44 Program members represent seven departments from four schools at Penn. RBI members have $12M in research grant funding (annual direct costs), of which $10.9M is peer-reviewed and $7M is NCI-funded. There were 654 cancer-related publications authored by Program members during the project period. Of these, 27% are intra-Programmatic, 35% are inter-Programmatic and 64% are multi- institutional. RBI has 36 R01-equivalents. Program members accrued 1,476 subjects to interventional trials, and 3,611 subjects to non-interventional trials.

项目摘要 – 放射生物学和成像计划 (RBI) 放射生物学和成像计划 (RBI) 旨在增进对以下相互作用的理解： 电离和非电离辐射对癌症和正常组织的治疗可减轻癌症负担。 通过与我们的社区外展和参与 (COE) 合作，我们的服务区域。 目标是： 1) 开发并表征改善癌症放射治疗的药物； 改变或询问免疫环境以改善治疗的放射生物学或成像方法 3）更深入地了解肿瘤微环境（TME）和代谢，以达到目的 利用这种理解来改善治疗反应； 4) 开发新的成像技术以最佳地指导 癌症护理；5) 了解质子的生物效应，以优化其临床应用并确定 哪些患者将从质子束治疗中受益最多 该计划由医学博士 Amit Maity 领导。 放射肿瘤学系教授兼执行副主席，Daniel Pryma 医学博士， Maity 和 Pryma 博士是放射学副教授兼核医学科主任。 NCI 资助的研究人员将他们的科学愿景带入该计划，该计划的重点是基础和 自上次更新以来，该计划已开始开展转化研究和研究者发起的试验。 领导者招募了新的初级和高级科学家，加强了协作性同行评审资金等等 介入性临床试验，尤其是研究者发起的试验（构成 Maity 博士和 Pryma 博士扩大了该计划对影像模式的关注。 和治疗诊断学，进一步增强了 RBI 中放射生物学和成像之间的整合和相互作用。 一项重大进展是质子转化和临床研究的大幅扩展 RBI 与其他 ACC 项目（包括肿瘤生物学、免疫生物学、 癌症治疗、乳腺癌、癌症控制、烟草和环境致癌，以及 儿科肿瘤学。 44 名计划成员代表宾夕法尼亚大学四所学校的七个部门。 成员拥有 1200 万美元的研究资助资金（年度直接费用），其中 1090 万美元经过同行评审， 700 万美元由 NCI 资助。项目成员在此期间撰写了 654 篇与癌症相关的出版物。 其中，27% 是项目内项目，35% 是项目间项目，64% 是多项目项目期间。 RBI 拥有 36 个 R01 等效项目，共有 1,476 名受试者参与干预试验。 3,611 名受试者接受非干预性试验。